Histone Deacetylase Inhibitors
- Technology Benefits
- Fluorescently labeled so that inhibitor can be visualizedEffective at lower concentrations.Act by a novel mechanism
- Detailed Technology Description
- Histone Deacetylase (HDAC) inhibitors can sensitize cancers tochemotherapy and radiation therapy. There are some HDAC inhibitors thatare currently being tested in clinical trials but there exists a needfor new and more effective HDAC inhibitors which are optimal withrespect to efficacy, toxicity, and isoform-specificity. The presentinvention describes fluorescently labeled novel HDAC inhibitors thatexert effects at lower concentrations with varying effectivenessagainst HDAC isoforms.
- *Abstract
-
- *Publications
- No relevant publications or resources.
- *Stage of Development
- Proof of concept demonstrated in cell lines and in prostate cancer animal models.
- Country/Region
- USA
For more information, please click Here
